196 related articles for article (PubMed ID: 19413685)
1. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat.
Abalo R; Cabezos PA; López-Miranda V; Vera G; González C; Castillo M; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2009 Sep; 21(9):1002-e80. PubMed ID: 19413685
[TBL] [Abstract][Full Text] [Related]
2. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors.
Abalo R; Cabezos PA; Vera G; López-Miranda V; Herradón E; Martín-Fontelles MI
Neurogastroenterol Motil; 2011 May; 23(5):457-67, e177. PubMed ID: 21303434
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat.
Abalo R; Cabezos PA; Vera G; López-Pérez AE; Martín MI
Neurogastroenterol Motil; 2013 May; 25(5):373-82, e292. PubMed ID: 23594243
[TBL] [Abstract][Full Text] [Related]
5. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
Landi M; Croci T; Rinaldi-Carmona M; Maffrand JP; Le Fur G; Manara L
Eur J Pharmacol; 2002 Aug; 450(1):77-83. PubMed ID: 12176112
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
[TBL] [Abstract][Full Text] [Related]
7. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
8. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
[TBL] [Abstract][Full Text] [Related]
9. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
Cluny NL; Vemuri VK; Chambers AP; Limebeer CL; Bedard H; Wood JT; Lutz B; Zimmer A; Parker LA; Makriyannis A; Sharkey KA
Br J Pharmacol; 2010 Oct; 161(3):629-42. PubMed ID: 20880401
[TBL] [Abstract][Full Text] [Related]
10. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
11. Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.
Radziszewska E; Bojanowska E
Med Sci Monit Basic Res; 2013 Jan; 19():6-11. PubMed ID: 23291632
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat.
Yüce B; Kemmer M; Qian G; Müller M; Sibaev A; Li Y; Kreis ME; Storr M
Neurogastroenterol Motil; 2010 Jun; 22(6):672-e205. PubMed ID: 20158615
[TBL] [Abstract][Full Text] [Related]
13. Influence of intracerebroventricular or intraperitoneal administration of cannabinoid receptor agonist (WIN 55,212-2) and inverse agonist (AM 251) on the regulation of food intake and hypothalamic serotonin levels.
Merroun I; Errami M; Hoddah H; Urbano G; Porres JM; Aranda P; Llopis J; López-Jurado M
Br J Nutr; 2009 May; 101(10):1569-78. PubMed ID: 19245736
[TBL] [Abstract][Full Text] [Related]
14. Effects of prenatal exposure to the CB-1 receptor agonist WIN 55212-2 or CO on the GABAergic neuronal systems of rat cerebellar cortex.
Benagiano V; Lorusso L; Flace P; Girolamo F; Rizzi A; Sabatini R; Auteri P; Bosco L; Cagiano R; Ambrosi G
Neuroscience; 2007 Nov; 149(3):592-601. PubMed ID: 17916407
[TBL] [Abstract][Full Text] [Related]
15. Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures.
Lemos JI; Takahashi RN; Morato GS
Psychopharmacology (Berl); 2007 Oct; 194(2):139-49. PubMed ID: 17546513
[TBL] [Abstract][Full Text] [Related]
16. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2.
Pandolfo P; Pamplona FA; Prediger RD; Takahashi RN
Eur J Pharmacol; 2007 Jun; 563(1-3):141-8. PubMed ID: 17374533
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
18. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
19. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
20. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
